26.54

3.81% -1.05

Vtv Therapeutics Inc (VTVT)

Overview News Price History Financials Discussions Forecast Stock Split

Vtv Therapeutics Inc stock is traded at $26.54, with a volume of 11,806. It is down -3.81% in the last 24 hours and down -12.87% over the past month. vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Previous Close:

$27.59

Open:

$27.4923

24h Volume:

11,806

Relative Volume:

0.49

Market Cap:

$104.94M

Revenue:

$36.84M

Net Income/Loss:

$-729.00K

P/E Ratio:

-28.73

EPS:

-0.9237

Net Cash Flow:

$-10.02M

1W Performance:

-14.88%

1M Performance:

-12.87%

6M Performance:

-27.78%

1Y Performance:

+27.66%

1-Day Range:

$25.95

$27.49

1-Week Range:

$25.95

$31.21

52-Week Range:

$19.50

$44.00

Vtv Therapeutics Inc Stock (VTVT) Company Profile

Name

Vtv Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

336-841-0300

Address

3980 PREMIER DR, HIGH POINT, NC

Employee

Twitter

@vTvTherapeutics

Next Earnings Date

2026-11-05

Latest SEC Filings

VTVT's Discussions on Twitter

Compare VTVT vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTVT Vtv Therapeutics Inc	26.54	104.94M	36.84M	-729.00K	-10.02M	-0.9237
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-26	Initiated	Rodman & Renshaw	Buy
Mar-12-26	Initiated	Evercore ISI	Outperform
Jan-23-26	Initiated	Roth Capital	Buy
Jan-05-26	Initiated	TD Cowen	Buy
Nov-19-25	Initiated	BTIG Research	Buy
May-30-19	Initiated	H.C. Wainwright	Buy
Apr-10-18	Downgrade	Stifel	Buy → Hold
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-08-18	Initiated	Northland Capital	Outperform
Sep-26-16	Initiated	H.C. Wainwright	Buy
Sep-04-15	Initiated	Canaccord Genuity	Buy
Aug-24-15	Initiated	Piper Jaffray	Overweight
Aug-24-15	Initiated	Stifel	Buy

View All

Vtv Therapeutics Inc Stock (VTVT) Latest News

Oct 15, 2026

iOnctura appoints Paul Sekhri as Chair of its Board of Directors - GlobeNewswire Inc.

Oct 15, 2026

Oct 08, 2026

Three parties report shared voting power over vTv Therapeutics (VTVT) shares in a passive stake amendment. - Stock Titan

Oct 08, 2026

Sep 15, 2026

A new hire gets 2,500 options to buy vTv shares at $31.44 each - Stock Titan

Sep 15, 2026

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 15, 2026

Sep 12, 2026

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com

Sep 12, 2026

Sep 09, 2026

vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research - marketbeat.com

Sep 09, 2026

Sep 04, 2026

Responsive Playbooks and the VTVT Inflection - news.stocktradersdaily.com

Sep 04, 2026

Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy - marketbeat.com

Sep 04, 2026

Sep 03, 2026

vTv Therapeutics (VTVT) Holds Steady at $33.40 as Shares Trade FlatDiamond Pattern - vinanet.vn

Sep 03, 2026

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com

Sep 03, 2026

Sep 02, 2026

A type 1 diabetes drug developer plans two investor events in September - Stock Titan

Sep 02, 2026

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving AverageShould You Sell? - marketbeat.com

Sep 02, 2026

Sep 01, 2026

vTv Therapeutics Q2 2026 Earnings: Net Loss Slightly Wider Than Estimates, Shares Edge HigherPerformance Review - dars.gov.et

Sep 01, 2026

Aug 31, 2026

vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - kalkine.ca

Aug 31, 2026

Aug 26, 2026

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High? - qz.com

Aug 26, 2026

Aug 19, 2026

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Aug 19, 2026

Aug 18, 2026

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 18, 2026

Aug 15, 2026

vTv Therapeutics (VTVT) Slips 2.37% to $30.12 as Support Holds in FocusDouble Top - vinanet.vn

Aug 15, 2026

vTv Therapeutics (VTVT) Slips 2.37% to $30.12 as Support Holds in FocusActive ETF Flow - dars.gov.et

Aug 15, 2026

Aug 14, 2026

The Technical Signals Behind (VTVT) That Institutions Follow - Stock Traders Daily

Aug 14, 2026

Aug 10, 2026

vTv Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

HC Wainwright Lowers Earnings Estimates for vTv Therapeutics - MarketBeat

Aug 10, 2026

Aug 09, 2026